← Back to Search

Monoclonal Antibodies

Pritumumab for Brain Cancer

Phase 1

Waitlist Available

Led By Jose A. Carrillo, MD

Research Sponsored by Nascent Biotech

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 months

Awards & highlights

Study Summary

This trial is studying the side effects and best dose of pritumumab when given by itself or together with bevacizumab in treating patients with gliomas or brain metastases.

Eligible Conditions

Brain Cancer
Brain Metastases

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

Secondary outcome measures

Intra-cranial Objective Response Rate

Trial Design

1Treatment groups

Experimental Treatment

Group I: PritumumabExperimental Treatment1 Intervention

Dose Escalation phase (3+3 patients): Pritumumab administered sequentially as 1-hour IV infusion, on Day 1, 8, and 22 of each 28-day treatment cycle at: 1.6 mg/kg, 4.8 mg/kg, 8.0 mg/kg, 12.0 mg/kg, and 16.2 mg/kg, for a maximum of 6 cycles or progression or unacceptable toxicity. Expansion phase (6-12 patients): Pritumumab administered as 1-hour IV infusion, on Day 1, 8, and 22 of each 28-day treatment cycle at or below MTD for a maximum of 6 cycles or progression or unacceptable toxicity.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Nascent BiotechLead Sponsor

Hoag Memorial Hospital PresbyterianOTHER

34 Previous Clinical Trials

14,653 Total Patients Enrolled

Jose A. Carrillo, MDPrincipal InvestigatorOne Hoag Drive Newport Beach, CA 92663, United States

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still positions available to participate in this experiment?

"According to records on clinicaltrials.gov, this trial is still seeking participants and was initially announced in March of 2021 before being updated recently in April 2022."

Answered by AI

Has the FDA granted its seal of approval to Pritumumab?

"With limited data backing its efficacy and safety, Pritumumab is ranked as a one on our team's scale of 1 to 3."

Answered by AI

How many individuals are being incorporated into this experiment?

"Affirmative. Clinicaltrials.gov records indicate that the trial, which was launched on March 18th 2021, is actively recruiting volunteers. The study requires 42 participants to be recruited from 2 distinct medical facilities."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Safety Study of Pritumumab in Brain Cancer

2021. "Safety Study of Pritumumab in Brain Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04396717.

All > Brain Cancer